IL140223A0 - Compositions containing a compound which binds to glucagon-liked - Google Patents

Compositions containing a compound which binds to glucagon-liked

Info

Publication number
IL140223A0
IL140223A0 IL14022399A IL14022399A IL140223A0 IL 140223 A0 IL140223 A0 IL 140223A0 IL 14022399 A IL14022399 A IL 14022399A IL 14022399 A IL14022399 A IL 14022399A IL 140223 A0 IL140223 A0 IL 140223A0
Authority
IL
Israel
Prior art keywords
liked
glucagon
binds
compound
compositions containing
Prior art date
Application number
IL14022399A
Other languages
English (en)
Original Assignee
Bionebraska Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22215287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL140223(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bionebraska Inc filed Critical Bionebraska Inc
Publication of IL140223A0 publication Critical patent/IL140223A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL14022399A 1998-06-12 1999-05-07 Compositions containing a compound which binds to glucagon-liked IL140223A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8904498P 1998-06-12 1998-06-12
PCT/US1999/010040 WO1999064061A1 (en) 1998-06-12 1999-05-07 GLUCAGON-LIKE PEPTIDE-1 IMPROVES β-CELL RESPONSE TO GLUCOSE IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE

Publications (1)

Publication Number Publication Date
IL140223A0 true IL140223A0 (en) 2002-02-10

Family

ID=22215287

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14022399A IL140223A0 (en) 1998-06-12 1999-05-07 Compositions containing a compound which binds to glucagon-liked
IL140223A IL140223A (en) 1998-06-12 2000-12-11 Pharmaceutical compositions containing exendin for treating impaired glucose tolerance

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL140223A IL140223A (en) 1998-06-12 2000-12-11 Pharmaceutical compositions containing exendin for treating impaired glucose tolerance

Country Status (30)

Country Link
US (1) US7265087B1 (cs)
EP (2) EP1419783A3 (cs)
JP (1) JP2002517469A (cs)
KR (1) KR20010052800A (cs)
CN (1) CN1209166C (cs)
AP (1) AP2001002027A0 (cs)
AT (1) ATE270897T1 (cs)
AU (2) AU758825B2 (cs)
BG (1) BG64975B1 (cs)
BR (1) BR9911112A (cs)
CA (1) CA2334872C (cs)
CZ (1) CZ294848B6 (cs)
DE (1) DE69918691T2 (cs)
DK (1) DK1083924T3 (cs)
EA (1) EA004538B1 (cs)
ES (1) ES2224659T3 (cs)
GE (1) GEP20033015B (cs)
HU (1) HUP0102193A2 (cs)
ID (1) ID28617A (cs)
IL (2) IL140223A0 (cs)
MX (1) MXPA00012286A (cs)
NO (1) NO20006336L (cs)
NZ (2) NZ527473A (cs)
OA (1) OA11694A (cs)
PL (1) PL195662B1 (cs)
PT (1) PT1083924E (cs)
SK (1) SK19042000A3 (cs)
TR (1) TR200100079T2 (cs)
UA (1) UA69412C2 (cs)
WO (1) WO1999064061A1 (cs)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO2001077137A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
US6344180B1 (en) 1999-06-15 2002-02-05 Bionebraska, Inc. GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
US20020025306A1 (en) * 2000-01-07 2002-02-28 Baetge Edward E. Methods of increasing the glucose responsiveness of pancreatic ss-cells
EP1346722B1 (en) 2000-12-01 2008-12-10 Takeda Pharmaceutical Company Limited Method for producing preparation containing bioactive substance
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
JP4681231B2 (ja) 2002-03-20 2011-05-11 マンカインド コーポレイション 吸入装置
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US8921311B2 (en) * 2003-08-01 2014-12-30 Mannkind Corporation Method for treating hyperglycemia
JP5078014B2 (ja) 2004-08-20 2012-11-21 マンカインド コーポレイション ジケトピペラジン合成の触媒反応
EP1791542B1 (en) 2004-08-23 2015-05-20 Mannkind Corporation Diketopiperazine salts for drug delivery
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
CN101184509A (zh) * 2005-05-27 2008-05-21 阿斯比奥制药株式会社 胰岛素抵抗性改善剂
KR101643478B1 (ko) 2005-09-14 2016-07-27 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
MX2008010721A (es) 2006-02-22 2008-09-01 Mannkind Corp Un metodo para mejorar las propiedades farmaceuticas de microparticulas que contienen dicetopiperazina y un agente activo.
JP2009534423A (ja) 2006-04-20 2009-09-24 アムジェン インコーポレイテッド Ｇｌｐ−１化合物
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
EP3421031A1 (en) 2006-08-09 2019-01-02 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
RU2413528C2 (ru) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
IL290847B2 (en) 2007-04-23 2024-11-01 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
US20100210559A1 (en) * 2007-09-11 2010-08-19 Mondobiotech Laboratories Ag Trap-14 as a therapeutic agent
EP2187950A1 (en) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
DK2293833T3 (en) 2008-06-13 2016-05-23 Mannkind Corp DRY POWDER INHALER AND MEDICINAL ADMINISTRATION SYSTEM
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
US20120058105A1 (en) * 2008-06-27 2012-03-08 Martin Kean Chong Ng Method of treatment of vascular complications
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8298561B2 (en) 2009-09-28 2012-10-30 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
JP6385673B2 (ja) 2010-06-21 2018-09-05 マンカインド コーポレイション 乾燥粉末薬物送達システム
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN105667994B (zh) 2011-04-01 2018-04-06 曼金德公司 用于药物药盒的泡罩包装
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
EP2873422A4 (en) 2012-07-10 2015-12-30 Takeda Pharmaceutical PHARMACEUTICAL PREPARATION FOR INJECTION
JP6312262B2 (ja) 2012-07-12 2018-04-18 マンカインド コーポレイション 乾燥粉末薬物送達システム
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
UA116553C2 (uk) 2012-12-21 2018-04-10 Санофі Пептидна сполука - агоніст рецептора glp-1 i glp
EP3021834A1 (en) 2013-07-18 2016-05-25 MannKind Corporation Heat-stable dry powder pharmaceutical compositions and methods
JP2016530930A (ja) 2013-08-05 2016-10-06 マンカインド コーポレイション 通気装置及び方法
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (ru) 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Пептид для лечения сахарного диабета 2-го типа и его осложнений
CN104267194B (zh) * 2014-09-23 2016-01-13 上海市东方医院 人胰高血糖素样肽-1、抗体及其试剂盒
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
MA44390A (fr) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc Systèmes de mise en place et de retrait d'implant
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
SG10201913699QA (en) 2016-05-16 2020-03-30 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
JP7350851B2 (ja) 2018-11-12 2023-09-26 天津薬物研究院有限公司 グルカゴン由来ペプチド及びその用途
CN113430154A (zh) * 2021-05-21 2021-09-24 深圳市前海金卓生物技术有限公司 分泌glp-1的蛋白表达系统及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9710452A (pt) 1996-06-05 1999-08-17 Boehringer Mannheim Gmbh Anïïlogos de exendina processos para sua prepara-Æo e medicamentos contendo os mesmos
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6344180B1 (en) * 1999-06-15 2002-02-05 Bionebraska, Inc. GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes

Also Published As

Publication number Publication date
DE69918691T2 (de) 2005-07-21
CN1209166C (zh) 2005-07-06
ID28617A (id) 2001-06-21
IL140223A (en) 2010-12-30
GEP20033015B (en) 2003-07-25
EP1083924A1 (en) 2001-03-21
WO1999064061A1 (en) 1999-12-16
TR200100079T2 (tr) 2001-06-21
BG105079A (en) 2001-09-28
BR9911112A (pt) 2001-11-27
JP2002517469A (ja) 2002-06-18
ES2224659T3 (es) 2005-03-01
MXPA00012286A (es) 2002-10-17
DK1083924T3 (da) 2004-11-22
AU3889999A (en) 1999-12-30
OA11694A (en) 2005-01-12
AU758825B2 (en) 2003-04-03
DE69918691D1 (de) 2004-08-19
BG64975B1 (bg) 2006-11-30
CA2334872A1 (en) 1999-12-16
EP1419783A3 (en) 2005-01-12
NZ527473A (en) 2005-02-25
AU2003212050B2 (en) 2006-02-16
EA004538B1 (ru) 2004-06-24
UA69412C2 (uk) 2004-09-15
KR20010052800A (ko) 2001-06-25
AP2001002027A0 (en) 2001-03-31
US7265087B1 (en) 2007-09-04
NO20006336L (no) 2001-02-12
PT1083924E (pt) 2004-10-29
SK19042000A3 (sk) 2001-11-06
AU2003212050A1 (en) 2003-08-14
HUP0102193A2 (hu) 2001-10-28
PL345212A1 (en) 2001-12-03
CA2334872C (en) 2014-08-19
CN1311687A (zh) 2001-09-05
CZ20004614A3 (en) 2001-06-13
PL195662B1 (pl) 2007-10-31
EA200100029A1 (ru) 2001-10-22
ATE270897T1 (de) 2004-07-15
NO20006336D0 (no) 2000-12-12
EP1419783A2 (en) 2004-05-19
CZ294848B6 (cs) 2005-03-16
EP1083924B1 (en) 2004-07-14
NZ508823A (en) 2003-10-31

Similar Documents

Publication Publication Date Title
IL140223A0 (en) Compositions containing a compound which binds to glucagon-liked
PL342629A1 (en) Organic compounds containing compositions
PL341372A1 (en) Cellecoxibe containing compositions
GB9822518D0 (en) Antiperspirant compositions
GB9516072D0 (en) Improved compositions containing organic compounds
GB9703531D0 (en) Improvements relating to chemical compositions
GB0119695D0 (en) Novel compound
GB9521837D0 (en) Improved compositions containing organic compounds
GB9516081D0 (en) Improved compositions containing organic compounds
IL139210A (en) Pharmaceutical composition containing a macrolide compound
EP1106639A4 (en) PHOTOCURABLE COMPOSITION CONTAINING AN IODONIUM SALT
ZA969510B (en) Improved compositions containing organic compounds
GB9612645D0 (en) Improved compositions containing organic compounds
GB2307915B (en) Improved compositions containing organic compounds
IL139733A0 (en) Novel compositions
GB9827431D0 (en) Novel compound
GB9803415D0 (en) Adhesive compositions
GB9808896D0 (en) Novel compound
GB9818258D0 (en) Antifungal compositions
GB9825721D0 (en) Adhesive compositions
GB9808894D0 (en) Novel compound
GB9726812D0 (en) Compound & composition
GB9817321D0 (en) Novel compound
GB9820404D0 (en) Novel compound
GB9815871D0 (en) Novel compound